{"entity":{"id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LRK-4189 escalation in advanced solid tumours, run by LARKSPUR BIOSCIENCES, INC., now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07498725 by LARKSPUR BIOSCIENCES, INC., with 120 participants planned, started 2026-07-07 and due to reach its primary completion in 2029-06. Interventions recorded: LRK-4189 escalation, LRK-4189 expansion, LRK-4189 optimization and Chemo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07498725","url":"https://clinicaltrials.gov/study/NCT07498725"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07498725","phase":"1/2","setting":"A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors","sponsor":"LARKSPUR BIOSCIENCES, INC.","enrolled":120,"outcomes":[]},"route":"/trials/nct07498725/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}